[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adverse-drug-reaction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adverse-drug-reaction":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,39,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100532969","the-texas-interprofessional-pharmacogenomics-ipgx-100532969",false,"NCT06219720","The Texas Interprofessional Pharmacogenomics (IPGx)","The Texas Interprofessional Pharmacogenomics (IPGx) PILOT Cohort","Inclusion Criteria:\n\n* People taking 5 or more medications, including over the counter drugs, supplements, natural products, cannabis produces, or other recreational drugs\n* Ability to give and comprehend the consent process.\n* Consent to donate urine samples, genetic data through buccal swabs, undergo a comprehensive history and physical examination.\n* All genders.\n* Age 45 and over\n\nExclusion Criteria:\n\n* Subject has been diagnosed or is being treated for any cancer other than basal cell cancer in the last 5 years. Patients with metastatic melanoma in the last 5 years will be excluded.\n* Admitted to hospice.\n* Patient has ever been diagnosed with Hepatitis B or C.\n* Patient has ever been diagnosed with active liver disease, hepatomegaly, grossly abnormal liver function. Meld score \\>10, ALT or AST \\>100U\u002FL or an AST\u002FALT ratio \\>2\n* Patients taking imidazole antifungal medication.\n* Declines to participate or interact with staff\u002Fshare their medical status.\n* A diagnosis of Alzheimer's disease\n* Pregnant patients will be excluded\n* Unable\u002Funwilling to consent.\n* Unable to verbally communicate and comprehend English\u002FSpanish language.","ALL","45 Years",{"count":19,"type":20},50,"ESTIMATED","180 Days","OBSERVATIONAL","The investigator's primary aim is to evaluate polypharmacy-associated adverse drug reactions (ADR) in a pilot study of at-risk patients using state-of-the-art pharmacogenomic technology and to use this information to make recommendations for optimization of pharmacotherapy regimens. The data from the pilot cohort will be used to optimize and integrate a customized electronic decision support (clinical semantic network; CSN) dashboard to identify drug regimens that should be modified, replaced, or discontinued. A secondary objective of the pilot study is to evaluate the capacity\u002Fsaturation of CYP P450 enzymatic pathways in polypharmacy patients. A third objective is to determine the feasibility of the planned informatics workflows between the CLIA lab, the EMR, and the Family Medicine Practice.",[25],"Adverse Drug Reaction","RECRUITING","2025-09-05",{"date":29,"type":30},"2025-09-12","ACTUAL",{"date":32,"type":30},"2021-12-15",{"date":34,"type":20},"2027-11",{"name":36,"class":37},"Texas A&M University","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":45,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":38},"100374368","pharmacogenetic-testing-of-patients-with-unwanted-adverse-drug-reactions-or-therapy-failure-100374368","NCT04154553","Pharmacogenetic Testing of Patients With Unwanted Adverse Drug Reactions or Therapy Failure","Inclusion Criteria:\n\n* New medication with known PGx association (preemptive)\n* Current medication with observation of adverse drug reactions probably linked to drugs with known PGx association (reactive)\n* Current medication with observation of therapy failure probably linked to drugs with known PGx association (reactive)\n* Current and\u002For new medication and a family history of adverse drug reactions\u002Ftherapy failure probably linked to drugs with known PGx association\n* Signed informed consent; for patients \\\u003C 14 years, the legal representative needs to sign the informed consent\n\nExclusion Criteria:\n\n* Insufficient German knowledge\n* Not able to personally visit to the study pharmacy",true,"2 Years",{"count":48,"type":20},400,"Genetic makeup of a patient influences the efficacy and safety profile of a drug. This study is to summarize individual cases, where Pharmacogenetics (PGx) has been applied during pharmaceutical care. The primary objective is the compilation of case reports, where pharmacogenetic testing is applied to determine the hereditable component of the patient's susceptibility to experience therapy failure and\u002For adverse drug reactions. The experience with the compiled cases will be basis for the development of a reliable standard of procedure for pharmacogenetic testing in the community pharmacy. The cases will be supplemented with information on additional Parameters reported in the literature to affect efficacy or safety of the respective drug.",[25,51],"Therapy Failure",[53,54,55,56,57],"pharmacogenetics","single nucleotide polymorphism","absorption, distribution, metabolism and excretion (ADME)","genotyping","pharmacogenetic testing","2025-05-09",{"date":60,"type":30},"2025-05-14",{"date":62,"type":30},"2019-10-15",{"date":64,"type":20},"2026-08",{"name":66,"class":37},"University Hospital, Basel, Switzerland",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":77,"conditions":78,"keywords":84,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":5},"100554367","active-pharmacovigilance-study-of-the-medicine-rinvoq-upadacitinib-100554367","NCT06498167","Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)","LOOK-UP","Inclusion Criteria:\n\n* Prescription of Rinvoq™ from January 1, 2024;\n* 18 years of age or older at the time of recruitment; and\n* Expressed consent to participate in the study.\n\nExclusion Criteria:\n\n* They have any degree of cognitive impairment that prevents them from responding to a questionnaire administered by telephone;\n* They are participating in a phase I, II, or III clinical trial;\n* They have a life expectancy of less than 1 month; or\n* They do not have a valid telephone contact.","18 Years",{"count":76,"type":20},150,"The LOOK-UP is an investigator-initiated clinical study with the aim of monitoring the post-marketing safety of the medicine Rinvoq™ (upadacitinib), which is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease. The Marketing Authorisation Holder is AbbVie Deutschland GmbH \\& Co. KG.",[79,80,81,82,25,83],"Inflammatory Disease","Drug Side Effect","Drug Use","Adverse Drug Event","Safety Issues",[85,86,87,88,89,90,91,92,93,94,95],"Upadacitinib","Rinvoq","Rheumatoid arthritis","Psoriatic arthritis","Axial spondyloarthritis","Atopic dermatitis","Ulcerative colitis","Crohn's disease","Pharmacovigilance risk","Drug safety monitoring","Patient Safety","2024-07-12",{"date":98,"type":30},"2024-07-15",{"date":100,"type":30},"2024-07-01",{"date":102,"type":20},"2024-12-31",{"name":104,"class":37},"Universidade do Porto"]